ZerviateTreatment for Allergic Conjunctivitis
U.S. FDA grants Priority Review for Nicox’s AC-170 New Drug Application
Sophia Antipolis, France., 21 June 2016 -- Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for AC-170, a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016. Such date is indicative and contingent upon the information (including data) to be eventually provided by Nicox in the review period.
The October PDUFA date means Nicox now has decisions expected from the FDA on two of its compounds, AC-170 and latanoprostene bunod, by the end of 2016.
AC-170 is a novel formulation of cetirizine, the active ingredient in Zyrtec®1, which has been developed for the first time for topical application in the eye for the treatment of ocular itching associated with allergic conjunctivitis. Cetirizine is a second generation antihistamine and mast cell stabilizer that binds competitively to histamine receptor sites to reduce swelling, itching and vasodilation. Cetirizine, as an approved oral drug, has a well-characterized systemic safety and efficacy profile with worldwide exposure representing more than 300 million patient-years2-3-4. AC-170 is covered by two granted U.S. patents expiring in 2030 and 2032.
Approval of the AC-170 NDA prior to 1st December 2016 will trigger a milestone payment of $35 million in Nicox shares to ex-Aciex shareholders or $10 million in Nicox shares if approval of the NDA is received after this date. AC-170 was developed by Aciex Therapeutics, Inc., which became a wholly-owned subsidiary of Nicox in October 2014 and was subsequently renamed Nicox Ophthalmics, Inc.
About allergic conjunctivitis
Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis. Conjunctivitis is an inflammation of the thin layer of tissue that lines the white surface of the eye and the inner surface of the eyelids. It is a common eye disease, especially in children, and may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light. Conjunctivitis can be caused by a viral or bacterial infection, or can be the result of an allergic reaction.
It is estimated that more than 75 million people suffer from allergic conjunctivitis in the U.S.5 and the prevalence ranges from 20% to 40%6-7. The annual U.S. market for the treatment of allergic conjunctivitis totals more than $800 million8.
2. Zyrtec® (Cross-discipline team-leader review).
3. Charlesworth, E.N., et al., Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase
reaction. J Allergy Clin Immunol, 1989. 83(5): p. 905-12.
4. Levi-Schaffer, F. and R. Eliashar, Mast cell stabilizing properties of antihistamines. J Invest Dermatol, 2009. 129(11): p. 2549-51.
5. Global Data: Allergic Conjunctivitis Market Analysis, September 2014.
6. Nathan RA, Meltzer EO, et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99(6)2:S808-S814.
7. Singh K, et al. Epidemiology of ocular and nasal allergy in the United States, 1988-1994. Journal of Allergy and Clinical Immunology; 2010. 126: 778–783.
8. IMS April 2014.
Source: Nicox S.A.
Posted: June 2016
- Nicox Announces PDUFA Date for Zerviate NDA - April 11, 2017
- Nicox Resubmits AC-170 (Zerviate) NDA to the U.S. FDA - March 9, 2017
- Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170 - October 10, 2016
- Nicox submits New Drug Application for AC-170 to U.S. FDA - April 19, 2016